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Abstract
Access to pediatric HIV treatment in resource-limited settings has risen significantly. However, little is known about the
quality of care that pediatric or adolescent patients receive. The objective of this study is to explore quality of HIV care and
treatment in Nigeria and to determine the association between quality of care, loss-to-follow-up and mortality. A
retrospective cohort study was conducted including patients #18 years of age who initiated ART between November 2002
and December 2011 at 23 sites across 10 states. 1,516 patients were included. A quality score comprised of 6 process
indicators was calculated for each patient. More than half of patients (55.5%) were found to have a high quality score, using
the median score as the cut-off. Most patients were screened for tuberculosis at entry into care (81.3%), had adherence
measurement and counseling at their last visit (88.7% and 89.7% respectively), and were prescribed co-trimoxazole at some
point during enrollment in care (98.8%). Thirty-seven percent received a CD4 count in the six months prior to chart review.
Mortality within 90 days of ART initiation was 1.9%. A total of 4.2% of patients died during the period of follow-up (mean: 27
months) with 19.0% lost to follow-up. In multivariate regression analyses, weight for age z-score (Adjusted Hazard Ratio
(AHR): 0.90; 95% CI: 0.85, 0.95) and high quality indicator score (compared a low score, AHR: 0.43; 95% CI: 0.26, 0.73) had a
protective effect on mortality. Patients with a high quality score were less likely to be lost to follow-up (Adjusted Odds Ratio
(AOR): 0.42; 95% CI: 0.32, 0.56), compared to those with low score. These findings indicate that providing high quality care
to children and adolescents living with HIV is important to improve outcomes, including lowering loss to follow-up and
decreasing mortality in this age group.
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Introduction
Though numerous challenges have limited scale-up of pediatric
antiretroviral therapy (ART), significant progress has been made.
[1–3] Access to pediatric ART in resource limited settings has
risen more than 7-fold from 75,000 children receiving ART in low
and middle income countries in 2005 to 562,000 by the end of
2011. [4] As pediatric treatment becomes more widely available,
determining standards for and measuring the quality of HIV care
and treatment that children receive has become a high priority. In
order to derive the full benefit of ART, children and adolescents
must be provided with high quality care and treatment that
addresses their multifaceted needs, including adherence counsel-
ing, disclosure support, laboratory monitoring, and opportunistic
infection screening along with other critical services.
The Institute of Medicine defines health care quality as the
extent to which health services provided to individuals and
populations improve desired health outcomes and are consistent
with current professional knowledge. [5] Performance indicators
are measurement tools that may be used to assess health care
quality. [6] These indicators fall into three categories: (1) structure
(characteristics of the health care setting such as human resource
availability); (2) process (aspects of the encounter with the patient
such as which tests are ordered); or (3) outcome (the patient’s
subsequent health status). [7–10] Structure and process may
influence outcome, indirectly or directly. [11] Understanding this
relationship is essential for quality improvement efforts, particu-
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procedural change are limited. Numerous studies conducted in
sub-Saharan Africa have assessed the impact of selected structural
changes, such as task-shifting and decentralization of services, on
HIV treatment outcomes. [12–17] Process indicators capturing
key services, such as semi-annual CD4 count monitoring, routine
opportunistic infection screening and regular adherence support,
are frequently collected for programmatic monitoring and
evaluation. However, the correlation between process indicators
such as these and clinical outcomes of HIV care and treatment has
not been well explored in resource limited settings. [18,19]
Moreover, quality assessment of pediatric HIV care and
treatment lags far behind that of adults internationally. Several
national programs have identified process and outcomes indicators
to guide improvement efforts. However, few reports of HIV care
quality that focus on pediatric or adolescent services have been
published. [20–22] Reports describing clinical outcomes in this age
group have documented significant challenges, with numerous
studies noting high rates of loss to follow-up and early mortality.
[23–28] Many factors—including late presentation, malnutrition,
lack of caregiver involvement, nondisclosure, and HIV-related
stigma—contribute to these findings. [27,29,30] Whether the
quality of care received by children and young adults is associated
with loss to follow-up or mortality has not been assessed. As
pediatric and adolescent ART becomes more widely available
globally, identifying appropriate measures of quality and deter-
mining their association with outcomes is critical and should help
guide future programmatic planning.
Nigeria is home to the second largest number of people living
with HIV in the world after South Africa. In 2012, approximately
3,400,000 people in Nigeria were living with HIV, including
430,000 children. [31] Though coordinated efforts have been
underway in Nigeria to increase access to ART for pediatric
patients since 2005, a significant disparity exists between pediatric
and adult ART coverage (7% versus 26%, respectively). [32]
Limited data exist describing clinical outcomes or quality of care in
pediatric or adolescent patients on ART in Nigeria. [33,34] The
objective of this study is to explore quality of care received by
pediatric and adolescent patients receiving ART in Nigeria and to
determine the association between quality of care and loss to
follow-up and mortality.
Methods
Ethical Review
The study protocol and assessment tools were submitted to the
National Health Research Ethics Committee of Nigeria (NHREC)
and approved on April 9th, 2011. Individual signed, written
informed consent from participants was waived by NHREC.
Patient information was de-identified prior to analysis. Unique
patient identifiers were assigned to each patient to protect patient
confidentiality.
Study design
A retrospective cohort study was conducted including patients
enrolled in care between November 2002 and December 2011.
This chart review was a component of a larger assessment of access
to pediatric and adolescent treatment services funded by the
United States Government/PEPFAR Nigeria Program. [File S1]
Purposive sampling was used to select 23 sites providing
antiretroviral therapy from 10 states across the 6 geopolitical
zones of Nigeria. At the time of this assessment, all pediatric HIV
care and treatment in Nigeria was provided at hospitals that
offered secondary and tertiary-level specialty services. The criteria
guiding site selection included geographic location and setting (i.e.,
urban, peri-urban, or rural). Safety concerns limited inclusion of
sites in certain states. All treatment sites are monitored by the
Federal Ministry of Health and supported by a variety of US
government funded implementing partners (IPs).
Charts representing 10% of the total number of patients 0–18
years of age receiving antiretroviral therapy (ART) in the 10 states
chosen were selected using random sampling. Each site was asked
to provide a list of all enrolled patients 0–18 years of age meeting
the inclusion criteria by medical record number. Chart design and
contents were standardized in 2008 to include the same variables
across all sites throughout the country, and sites maintained either
paper or electronic records.
Patients were eligible for inclusion in the study if they were 0–18
years of age and initiated ART during the study period. Follow-up
was censored either at the time of the loss to follow-up (as defined
below), death or the end of the study period.
Outcomes
The two main outcomes were lost to follow-up and death. Loss
to follow-up was defined as no evidence of a visit to the clinic or
drug pick up for 90 days following the last scheduled appointment
as documented in the chart. Death was only counted if verified by
the patient’s family or if death occurred within the hospital.
Independent variables including quality of care
indicators
The primary independent variable of interest was a quality
score comprised of six process indicators: (1) screening for
tuberculosis at entry into care, (2) adherence measurement at last
visit, (3) adherence counseling at last visit, (4) prescription of co-
trimoxazole at any time since enrollment, (5) at least one CD4
count in the last six months, and (6) documented weight at last
visit. These indicators are recommended by the World Health
Organization and should be standard components of clinical
practice as outlined by the 2005 and 2010 National Guidelines on
Paediatric HIV and AIDS Treatment and Care in Nigeria.
[35,36] Recommendations regarding these process indicators did
not change over time. Similar indicators have been used to assess
pediatric HIV care and treatment quality in other studies
conducted in resource limited settings. [22] Screening for
tuberculosis in pediatric and adolescent patients includes symptom
assessment (poor weight gain, fever, and cough), determination of
contact history with a known TB case, clinical examination and
radiology followed by sputum induction, if warranted. The
standard procedure for adherence assessment in HIV clinics in
Nigeria is to ask the patient or the caregiver the number of ART
doses missed within the last three days. Review of pharmacy
records, returned syrup measurement and pill counting are not
routinely conducted. Adherence counseling should be offered at
every visit. More intensive counseling is provided if the patient or
caregiver reports missed ART doses. CD4 count testing and co-
trimoxazole are provided free of charge at all sites. A quality score
was calculated with one point assigned for each service received
and zero points assigned if the service was not received, for a total
of six points. For ease of interpretation, the score was categorized
into ‘‘high quality’’ versus ‘‘low quality’’ using the median score as
a cutoff for bivariate and multivariate regression models.
Additional patient characteristics and clinical variables related
to the outcomes of interest were also collected including: gender,
age at ART initiation, CD4 count/percentage (baseline and most
recent value), baseline weight/height (to determine age-for-weight
z-score), current ART regimen, and facility type (rural, peri-urban
and urban). Viral load measurement was not standard of care
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outcome measure.
Baseline immunosuppression at entry into care was calculated
using patient age and either initial CD4 count or initial CD4
percentage. For patients less than two years of age, ‘‘severe
immunosuppression’’ was defined as an initial CD4 count less than
750 cells/mm
3 or a percentage less than 15%, while ‘‘moderate
immunosuppression’’ was defined as CD4 count between 750 and
1500 cells/mm
3 or a percentage of between 15% and 25%. ‘‘No
immunosuppression’’ was defined as an initial CD4 count of
1500 cells/mm
3 or more or a percentage of 25% or more. For
patients between two and five years of age, ‘‘severe immunosup-
pression’’ was defined as an initial CD4 count less than 500 cells/
mm
3 or percentage less than 15%, ‘‘moderate immunosuppres-
sion’’ as an initial CD4 count of between 500 and 1000 cells/mm
3
or percentage of between 15% and 25%, and ‘‘no immunosup-
pression’’ as an initial CD4 count of 1000 cells/mm
3 or more or
percentage of 25% or more. For patients five years of age or older,
‘‘severe immunosuppression’’ was defined as an initial CD4 count
less than 200 cells/mm
3 or percentage less than 15%, ‘‘moderate
immunosuppression’’ as an initial CD4 count of between 200 and
500 cells/mm
3 or percentage of between 15% and 25%, and ‘‘no
immunosuppression’’ as an initial CD4 count of 500 cells/mm
3 or
more or percentage of 25% or more. [35]
Data Analysis
Means and standard deviations were computed for continuous
variables and counts with percentages for categorical variables.
Differences in mortality and loss to follow-up by age group and
differences in quality indicators by year of initial visit were
compared using chi-square statistics. Bivariate methods were used
to examine the relationships of individual independent variables
with the primary outcomes of survival and loss-to-follow up,
including Kaplan-Meier estimation with log rank testing. One
predictor Cox proportional hazards regression models were used
for survival and one predictor logistic regression models for loss to
follow-up.
In survival analyses, associations were estimated using hazard
ratios (HR) with 95 percent confidence intervals (CI). In the
analysis of loss to follow-up, associations were estimated using odds
ratios (OR) with 95 percent CIs. The multivariate logistic
regression models included independent variables that were
significant in the bivariate models defined as p,0.05 and/or
were potential confounders of the relationship between the quality
score and the outcomes (e.g., weight for age (z-score) and age at
ART initiation). The multivariate Cox regression model was
limited to four predictors due to the number of deaths in the
sample, using a guide of ten events or deaths required per
predictor. [37]
The proportional hazards assumption was checked by graphical
methods and by testing interaction terms that included the log of
follow-up time. The discrimination ability of the logistic models
was measured by c-statistics with calibration assessed using
Hosmer-Lemeshow chi-square statistics and their associated p-
values. Where data were sufficient, we tested for interactions
among the independent variables in these models. Patient-level
variability across sites was investigated using the intra-cluster
correlation coefficient (ICC). The ICC was close to zero,
indicating similarity between within-site variability and variability
across sites. We employed an alpha of 0.05 in all statistical tests to
determine statistical significance. All data management and
statistical analyses were performed using SAS for Windows version
9.2.
Results
Study population
A total of 1,516 patients were sampled from 23 sites. Most
patients (73.6%) received care at urban facilities (Table 1). The
average human resource distribution for pediatric HIV care and
treatment was similar across facilities with an average of 23 full-
time clinical staff (including doctors, nurses, pharmacists and
counselors) per site. Approximately one-quarter of patients were
24 months old or younger at ART initiation, while 40.0% were
between two and six years old, 21.1% were six to nine years old,
and 14.9% were 10 to 18 years old (Table 1). Most patients had an
initial visit and initiated ART between 2008 and 2011. Approx-
imately one-half of patients were male (52.8%). Almost half of
patients were severely immunosuppressed at baseline (46.3%),
32.5% were moderately immunosuppressed, and 21.3% were not
immunosuppressed. The mean weight for age (z-score) at baseline
was 21.08 (64.04).
The mean duration of follow-up time was 27.7 months (619.7).
Most patients were on an ART regimen comprised of AZT/3TC/
NVP (81.5%) at the time of chart review. For those on regimens
containing d4T, the mean length of time on the regimen was 36.7
months (618.5).
Quality of care
Most patients were screened for tuberculosis at entry into care
(81.3%) and had adherence counseling at their last visit (89.7%)
(Table 1). Similarly, the majority of patients had their adherence
measured at their last visit (88.7%). Almost all patients had been
prescribed co-trimoxazole at some point during their enrollment in
care (98.8%). Weight for age was documented at the last visit in
72.2% of charts evaluated. However, less than half of patients alive
and in care at the time of the chart review had obtained a CD4
count in the six months prior to chart review (37.0%). A higher
percentage of patients who were .10 years old were screened for
TB compared to those who were ,10 years (87.4% vs. 80.3%,
p=0.0148). Over half of patients had a quality score of the median
or higher (greater than four points out of six) (55.5%). No
significant difference was noted in overall quality score between
adolescents (10–18) and younger patients (p=0.325).
Two quality indicators improved over time. The percentage of
patients with a CD4 count in the last six months (p,0.0001) and
weight for age documented at the last visit (p=0.0034) was higher
for those with an initial visit in more recent years (2008 to 2011)
than for those who enrolled in care prior to 2008.
Outcomes
Documented mortality within 90 days of ART initiation was
1.9% (Table 2). A total of 4.2% of patients died during the period
of follow-up. Mortality was highest for those 24 months old or less
at ART initiation (35.9%) (p=NS). Loss to follow-up was 19.0%
during the follow-up period, with 3.6% of patients lost within six
months of ART initiation and 6.9% lost within the first twelve
months. Loss to follow-up was highest for those 25 to 71 months
old at ART initiation (35.9%), compared to the other age groups
(p=0.0130). No significant difference was noted in mortality or
loss to follow-up between adolescents (age 10–18) and younger
patients (p=0.583 and p=0.565, respectively).
Bivariate results
Patients with a high quality score were more likely to survive
over time (p=0.0011) and less likely to be loss to follow-up (p,
0.0001) than patients with a low quality indicator score (Figures 1
and 2). Gender was not statistically significant in bivariate results
Quality of HIV Care and Pediatric and Adolescent Treatment
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All Patients (n=1516)
N Mean (SD) or %
Demographics
Age at ART initiation
0–24 months 363 24.0%
25–71 months 605 40.0%
6–9 years 318 21.1%
10–18 years 225 14.9%
Gender (Male) 799 52.8%
Clinical factors
Baseline immunosuppression
1
Severe 666 46.3%
0–24 months 165 24.8%
25–71 months 256 38.4%
6–9 years 124 18.6%
10–18 years 121 18.2%
Moderate 468 32.5%
0–24 months 106 22.7%
25–71 months 202 43.3%
6–9 years 92 19.7%
10–18 years 67 14.4%
No suppression 306 21.3%
0–24 months 47 15.4%
25–71 months 126 41.3%
6–9 years 97 31.8%
10–18 years 35 11.5%
Weight for age (z-score) 1382 21.08 (+4.04)
Most recent CD4 count among those alive
,350 cells/mm
3 369 27.3%
$350 cells/mm
3 983 72.7%
Treatment
Duration of follow-up in months 1511 27.7 (+19.7)
Current ART regimens
AZT/3TC/NVP 1236 81.5%
Regimens containing d4T 81 5.3%
Other regimen 196 13.0%
Patients enrolled by facility type
Rural 199 13.1%
Peri-urban 201 13.3%
Urban 1116 73.6%
Quality indicators
Screened for tuberculosis at entry into care 1115 81.3%
Adherence counseling documented at last visit 1311 89.7%
Adherence measured at last visit 1296 88.7%
Ever prescribed co-trimoxazole 1482 98.8%
Alive and not lost to follow up with at least one CD4 count in last six months 518 37.0%
Weight documented in chart at patient’s last visit 1049 72.2%
High quality indicator score
2 842 55.5%
1For patients less than two years of age, severe immunosuppression was defined as an initial CD4 count less than 750 cells/mm
3 or percentage less than 15%, moderate
immunosuppression as an initial CD4 count of between 750 and 1500 cells/mm
3 or percentage of between 15% and 25%, and no immunosuppression as an initial CD4
count of 1500 cells/mm
3 or more, or percentage of 25% or more. For patients between two and five years of age, severe immunosuppression was defined as an initial
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for age z-score had a protective effect on mortality (HR: 0.90; 95%
CI: 0.85, 0.95) (Table 3). Patients 24 months or younger at ART
initiation had a greater likelihood of death (HR: 1.76; 95% CI:
1.06, 2.94) and loss to follow-up (OR: 1.56; 95% CI: 1.16, 2.09),
compared to those older than 24 months at ART initiation.
Patients with severe immunosuppression were more likely to die
(HR: 6.11; 95% CI: 1.89, 19.76) and be lost to follow-up (OR:
1.48; 95% CI: 1.02, 2.14) than patients with no suppression.
Overall, a high quality score had a protective effect on mortality
(HR: 0.43; 95% CI: 0.26, 0.73) and loss to follow-up (OR: 0.40;
95% CI: 0.31, 0.53) compared to those with a low score.
Multivariate results
In multivariate Cox regression analyses, adjusting for other
factors, weight for age z-score (AHR: 0.92; 95% CI: 0.87, 0.98)
and high quality score (compared a low score, AHR: 0.47; 95%
CI: 0.26, 0.87) had a protective effect on mortality. Patients with
severe baseline immunosuppression were more likely to die than
those with no immunosuppression (AHR: 7.21; 95% CI: 1.72,
30.21) (Table 3). Adjusting for other factors in multiple logistic
regression analysis, patients with a high quality score were less
likely to be lost to follow-up (AOR: 0.42; 95% CI: 0.32, 0.56),
compared to those with low score.
Discussion
To our knowledge, this is the first report of a pediatric and
adolescent HIV care and treatment quality assessment in Nigeria.
Our findings suggest that providing high quality care to children
and adolescents living with HIV is associated with lower loss to
follow-up and mortality, providing compelling evidence that
investing in quality has the potential to retain this age group in
care and save lives.
In this study, six process indicators were selected to measure
quality. Overall, receipt of services was high. More than 80% of
patients were screened for TB at entry into care. However, a
higher percentage of adolescents were screened for TB compared
to pediatric patients. Though the World Health Organization
recommends screening for TB in pediatric patients as described,
under-diagnosis and diagnostic delays are common. [38] Intensive
training and improved strategies for early TB diagnosis in this age
group are needed. Adherence was measured, and adherence
counseling was provided to nearly 90% of patients at their last
visit. Almost all patients were started on co-trimoxazole at some
point since enrollment. Weight for age (z-score) was documented
in approximately 70% of charts. The percentage of patients with
documented weight for age (z-score) increased in 2008–2011
compared to previous years. Increasing site level experience,
improved availability of resources (scales) and training may have
contributed to this difference. Low quality scores were largely due
to deficits in receipt of CD4 count testing within 6 months of the
chart review. The low rates of CD4 count testing may have been
due to human resource deficits, dysfunctional equipment, reagent
stock-outs, or limited ability to transport samples to a central lab
facility, all common challenges identified in a larger assessment of
these sites. [File S1]
The quality score devised for this study was significantly
correlated with both loss to follow-up and mortality, with a higher
score associated with decreased loss to follow-up and increased
survival. This finding correlates with limited data from studies in
the US demonstrating the association between quality of HIV care
and clinical outcomes. [39,40] In this study, survival may have
been lower in patients who did not receive selected process
indicators because sub-optimal adherence and treatment failure
were missed. Many of the patients who were lost to follow-up may
have been too ill to return to the clinic. Higher weight for age z-
score had a protective effect on mortality. Numerous studies have
also noted this finding. [41–44]
Very limited clinical outcomes data are currently available from
the Nigerian pediatric and adolescent HIV treatment program.
Though the focus of this study was not solely on clinical outcomes,
this study provides a reasonable estimate of loss to follow-up and
mortality within the Nigerian national program. Early mortality
was 1.9% across all age groups, while mortality during the period
of follow-up was noted to be 4.2%. Compared to data from similar
pediatric and adolescent cohorts in sub-Saharan Africa, mortality
was lower in the Nigerian program. [44,45] Similar to other
studies, loss to follow-up was high at 19.0%. [46,47]
This study has several limitations. Sites were not randomly
selected because we wanted to include a geographically diverse
sample. Furthermore, we were limited to certain states due to
safety concerns. We did not measure all site characteristics that
may have impacted the process indicators included in the quality
score in this study. This was because our goal was to focus on
process, not structure. Furthermore, we knew from a larger
assessment that all the sites had similar resource availability. [File
S1] Though we provided an estimate of pediatric program staffing,
we were unable to account for individual provider characteristics
CD4 count less than 500 cells/mm
3 or percentage less than 15%, moderate immunosuppression as an initial CD4 count of between 500 and 1000 cells/mm
3 or
percentage of between 15% and 25%, and no immunosuppression as an initial CD4 count of 1000 cells/mm
3 or more, or percentage of 25% or more. For patients
between five years of age or older, severe immunosuppression was defined as an initial CD4 count less than 200 cells/mm
3 or percentage less than 15%, moderate
immunosuppression as an initial CD4 count of between 200 and 500 cells/mm
3 or percentage of between 15% and 25%, and no immunosuppression as an initial CD4
count of 500 cells/mm
3 or more, or percentage of 25% or more.
21 point assigned for each service received (screened for tuberculosis, adherence counseling at last visit, adherence measured by patient/caregiver self-report at last
visit, ever prescribed co-trimoxazole, alive and not lost to follow-up with at least one CD4 count in the last six months, and weight documented in chart at patient’s last
visit, and 0 points assigned if the service was not received, for a total of 6 points. A high score was defined as having the median score or above (.4 points).
doi:10.1371/journal.pone.0100039.t001
Figure 1. Kaplan-Meier survival by quality indicator score (high
vs. low).
doi:10.1371/journal.pone.0100039.g001
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patients living with HIV or specialty training which may have
impacted performance measures. In addition, as death was only
documented in the chart if confirmation was obtained from the
patient’s family or caregiver or if death occurred in the hospital, it
is not possible to know how many patients who were lost to follow
up were actually dead. Staff members were trained to contact
caregivers when patients were loss to follow-up, but standards
regarding the timeliness of this contact were not well defined, and
deaths may have been missed. Lastly, accurate measurement of
quality is largely dependent upon the accuracy of documentation
which is challenging to confirm in a retrospective study.
Pediatric and adolescent access to antiretroviral therapy in
Nigeria is expanding. Since 2013, the number of facilities across
the country that provide ART to children and adolescents has
increased significantly. In order to expedite access to treatment,
decentralization or down-referral of pediatric care to primary
health clinics has been initiated. Efforts are also underway to
standardize services across facilities and to ensure that quality
improvement is incorporated into regular in service training.
[Federal Ministry of Health of Nigeria, Personal Communication,
January 15, 2013] As pediatric and adolescent ART access
continues to expand in Nigeria and in similar resource limited
settings, ensuring the quality of care that patients receive will be
essential to reducing mortality and loss to follow-up. The next
logical step toward achieving this goal in the Nigerian treatment
program would be to use these data to inform a quality
improvement intervention. Quality improvement studies are
infrequently published in the medical literature. However, a few
studies have demonstrated the efficacy of quality improvement in
HIV care and treatment in resource limited settings. [48–50]
More broadly, quality improvement methods strengthen health
systems and help program planners utilize scarce resources more
efficiently. [51] Considering the enormous investment that has
been made in expanding access to pediatric and adolescent HIV
treatment, assessments of quality followed by the development of
appropriate interventions are critically important to maximize the
benefits of ART.
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File S1 Greeson D, Ojikutu B, Kolapo U, Higgins Biddle M,
CabralH,etal.(2012) Rapidassessment ofpediatricHIVtreatment
in Nigeria. Arlington, VA: USAID’s AIDS Support and Technical
Assistance Resources, AIDSTAR-One, Task Order 1. Available
at: http://www.aidstar-one.com/focus_areas/treatment/resources/
report/pediatric_tx_nigeria. Accessed 2013 Dec 14.
(PDF) Figure 2. Kaplan-Meier loss to follow-up by quality indicator
score (high vs. low).
doi:10.1371/journal.pone.0100039.g002
Table 2. Mortality and loss to follow-up by age at ART initiation.
Mortality n % p value
1
Within 90 days of ART Initiation 30 1.9%
During period of follow-up 64 4.2%
By age at ART initiation
0–24 months 23 35.9% NS
25–71 months 20 31.3%
6–9 years 13 20.3%
10–18 years 8 12.5%
Loss to follow-up
Within 6 months of ART Initiation 52 3.6%
Within 12 months of ART Initiation 100 6.9%
During period of follow-up 276 19.0%
By age at ART initiation
0–24 months 83 30.4% p=0.0130
25–71 months 98 35.9%
6–9 years 48 17.6%
10–18 years 44 16.1%
1Differences between age groups significant at p,0.05.
NS, not significant.
doi:10.1371/journal.pone.0100039.t002
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